Filter By Category
Archives
Share on -
ATABECESTAT
Generic Name: ATABECESTAT
ABSTRACT -
Atabecestat is an oral beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor formerly investigated to reduce amyloid-beta production in Alzheimer disease. Clinical development was discontinued because of safety concerns and unfavorable benefit-risk findings. It is not an approved treatment for Alzheimer disease and should not be used outside an authorized research context.
DOSAGE -
No approved dosage is available. It should not be administered outside an authorized research context. Historical trial dosing should not be used clinically.
SIDE EFFECTS–
- Possible or reported side effects may include:
- Elevated liver enzymes
- Neuropsychiatric symptoms
- Sleep disturbance
- Headache
- Nausea
- Falls or dizziness
- Cognitive worsening signal in the BACE-inhibitor class
- Rash
ALLERGIC REACTIONS -
Hypersensitivity may include rash, hives, swelling, wheeze, or anaphylaxis.
DRUG INTERACTIONS-
Use caution with:
- Other investigational Alzheimer therapies
- Hepatotoxic medicines
- CNS-active medicines that increase sedation, confusion, or fall risk
- Alcohol or sedatives
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, and supplements they are using.
PREAUTIONS–
- Avoid clinical use because development was discontinued.
- If encountered in a study history, review liver function, cognition, mood, and concomitant medicines.
WARNINGS –
- Not an approved Alzheimer treatment.
- Potential liver and cognitive/neuropsychiatric safety concerns require medical review.
- Keep out of reach of children.
- In case of overdose, severe reaction, or clinical deterioration, seek immediate medical attention.
Share on -
. Developed by